Faron’s Post

I knew I should have worn a jacket! Thanks again to Faron for inviting us along to speak at their capital markets day and present our work on payer interviews, KOL interviews and epi forecasting. If you want to watch the presentation you can see it in the link below. #biotech #marketresearch #pricing #forecasting PharmaVentures

Just a quick bump for Ralph Hughes who has been doing a great job building out our pricing and market access practice. He recently presented some of their work at Faron's recently capital markets day. Jacket or no jacket, its a good piece of analysis on the potential of #Bexmarilimab in MDS. #marketaccess #mds #biotech #marketresearch

Extracellular vesicles (EVs) are garnering immense interest for their potential in diagnostics, therapeutics, and as biomarkers for a myriad of diseases. As the research community delves deeper into the microscopic marvels of EVs, the demand for technology advancement has surged. Learn more about how innovative tools from BD Biosciences can help you accelerate your discoveries. https://lnkd.in/em_yzWTM #BDBiosciences #flowcytometry #FACS

I'm pleased to announce that Accelerator Life Science Partners portfolio companies Automera, Proniras Corporation, and Kayothera will be represented at #JPMHC2025 - the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco this January. These companies exemplify innovation and are advancing science in critical therapeutic areas: Automera recently closed $16M in Series A funding to propel its pioneering autophagy-targeting chimera platform. Proniras Corporation has begun enrolling patients in its Phase 1 study of Tezampanel for the treatment of opioid withdrawal, marking an important step in addressing substance use disorders. Kayothera is progressing KAYO-1609, the first retinoid pathway inhibitor to enter IND-enabling studies, offering new hope in oncology. If you’ll be attending #JPM2025 (January 13–16) and would like to connect with these companies, please reach out via LinkedIn. Accelerator Life Science Partners remains steadfast in its commitment to advancing transformative solutions that address some of the most pressing challenges in healthcare. #jpmhc2025 #biotech #healthcareinnovation

🌟 Join the Sharpest Minds in RNAi at the 6th RNAi-Based Therapeutics Summit! 🌟 Whether you're a seasoned RNAi pro or intrigued by its groundbreaking potential, here's why this is the event you can't miss: 🧠 28 Expert Speakers - Leading voices in the RNAi space, sharing brand-new data on targeting the placenta, kidney, muscle and adipose tissue 💬 2 Round Table Discussions - Dive deep into the hottest industry topics and and RNAi innovations for future opportunities with peers 💼 1 Investor Panel - Led by Eli Lilly and Company, Sunrise BioVentures, and Broadview Ventures Inc, discover what’s next in RNAi and the key factors investors are looking for Download the OFFICIAL BROCHURE: https://ter.li/4cb7jb This summit will bring together fellow RNAi peers and YOU could be part of it! Don’t miss your chance to network, learn, and lead the way in RNAi-based therapies. #RNAiTherapeutics #RNAiInnovation 

Join the Sharpest Minds in RNAi at the 6th RNAi-Based Therapeutics Summit! Whether you're a seasoned RNAi pro or intrigued by its groundbreaking potential, here's why this is the event you can't miss: 28 Expert Speakers - Leading voices in the RNAi space, sharing brand-new data on targeting the placenta, kidney, muscle and adipose tissue 2 Round Table Discussions - Dive deep into the hottest industry topics and and RNAi innovations for future opportunities with peers 1 Investor Panel - Led by Eli Lilly and Company, Sunrise BioVentures, and Broadview Ventures Inc, discover what’s next in RNAi and the key factors investors are looking for Download the OFFICIAL BROCHURE: https://ter.li/gvctqw This summit will bring together fellow RNAi peers and YOU could be part of it! Don’t miss your chance to network, learn, and lead the way in RNAi-based therapies. #RNAiTherapeutics #RNAiInnovation

Today our lab discussed a fascinating study exploring the role of type III IFNs in gut tissue damage and repair. Published: https://lnkd.in/g_94g_xC Preprint: https://lnkd.in/gB4n-6JT As a team deeply invested in interferons—especially type III IFNs—I’m always intrigued by research uncovering unique, non-redundant roles for IFN lambdas. It’s been widely accepted that type I and type III IFNs share signaling pathways via the same JAKs and STATs. But mounting evidence is challenging this narrative, suggesting there’s more to the story. * https://lnkd.in/giQyqvvh * https://lnkd.in/gjZan5_b And where it gets even more exciting is that emerging data hints that these signaling pathways might not be as similar as we thought. * https://lnkd.in/gktVnu4F * https://lnkd.in/gh6aPrnt * https://lnkd.in/g5bJQpVW What additional insights will the next study bring? Could these findings pave the way for a new generation of type III IFN-focused therapeutics? I think there’s a lot of potential here! What are your thoughts? Feel free to share with myself or fellow lab members Zhijie Chen shima shabani Mukesh Kumar Venkatramani!

In Basel this week? Need expert biomarkers support? Go see Ewa Stypka and Giulia Tagliavini and find out how Concept Life Sciences can guide and accelerate your #biomarker #discovery #OGBiomarkers #BiomarkersEU24

🌟 Join the Sharpest Minds in RNAi at the 6th RNAi-Based Therapeutics Summit! 🌟 Whether you're a seasoned RNAi pro or intrigued by its groundbreaking potential, here's why this is the event you can't miss: 🧠 28 Expert Speakers - Leading voices in the RNAi space, sharing brand-new data on targeting the placenta, kidney, muscle and adipose tissue 💬 2 Round Table Discussions - Dive deep into the hottest industry topics and and RNAi innovations for future opportunities with peers 💼 1 Investor Panel - Led by Eli Lilly and Company, Sunrise BioVentures, and Broadview Ventures Inc, discover what’s next in RNAi and the key factors investors are looking for Download the OFFICIAL BROCHURE: https://ter.li/4cb7jb This summit will bring together fellow RNAi peers and YOU could be part of it! Don’t miss your chance to network, learn, and lead the way in RNAi-based therapies. #RNAiTherapeutics #RNAiInnovation 

This weekend at the American Society of Hematology (ASH) Annual Meeting, I spoke with Dr. Abhishek Maiti from MD Anderson about a promising new treatment, developed by ImCheck Therapeutics for patients with AML.   Dr. Maiti presented fascinating data on a first-in-class gamma delta-2 T cell activator that shows promise for patients over 75 or those unfit for traditional transplant therapy. This is a population with significant unmet need and historically poor outcomes (< 15% 4-year survival).   Key highlights from the Phase 1 EVICTION study: - Impressive 50% CR rates and 90% composite CR rates in early data - Relatively tolerable safety profile comparable to current standards of care - Early promising results in poor prognosis patients - Novel mechanism targeting gamma delta-2 T cells, which are crucial for graft-versus-leukemia effects   The team is now working on analyzing the data as it matures, which will guide next steps towards a registrational trial. It's exciting to see innovative approaches like this bring hope to patients who currently have limited treatment options.   Congrats to the team, led by ImCheck's CMO Stephan Braun. Looking forward to watching this development program progress! #biotech #CMO #ASH24 #AML #FDAHematology #FastTrack Precision For Medicine Precision Medicine Group